1. |
Zhang S, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2015. J Natl Cancer Cent, 2021, 1(1): 2-11.
|
2. |
Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries. Lancet Glob Health, 2018, 6(5): e555-e567.
|
3. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
4. |
Gao YB, Chen ZL, Li JG, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet, 2014, 46(10): 1097-1102.
|
5. |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021. 肿瘤预防与治疗, 2021, 34(12): 1164-1200.
|
6. |
Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2. 2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2019, 17(7): 855-883.
|
7. |
Li N, Huang HY, Wu DW, et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: A systematic review. Lancet Oncol, 2019, 20(11): e619-e626.
|
8. |
Yang YM, Hong P, Xu WW, et al. Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther, 2020, 5(1): 229.
|
9. |
Akin Telli T, Bregni G, Camera S, et al. PD-1 and PD-L1 inhibitors in oesophago-gastric cancers. Cancer Lett, 2020, 469: 142-150.
|
10. |
黄钦, 王玉珠, 范乙, 等. 药物临床试验登记与信息公示平台介绍及常见问题分析. 中国新药杂志, 2014, 23(23): 2721-2724.
|
11. |
庄洁, 王莉文, 王景田. 建立药品说明书数据库查询系统的方法. 首都医药, 2005, 2: 38.
|
12. |
吴大维, 黄慧瑶, 唐玉, 等. 2020年中国肿瘤药物临床试验进展. 中华肿瘤杂志, 2021, 43(2): 218-223.
|
13. |
王书航, 方元, 黄慧瑶, 等. 2019中美肺癌药物临床试验横断面比较研究. 中国胸心血管外科临床杂志, 2020, 27(3): 327-331.
|
14. |
Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs. placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial. JAMA, 2021, 326(10): 916-925.
|
15. |
Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): A multicentre, randomised, open-label, phase 3 study. Lancet Oncol, 2020, 21(6): 832-842.
|
16. |
Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study. Lancet, 2021, 398(10302): 759-771.
|
17. |
Kojima T, Shah MA, Muro K, et al. Randomized phase Ⅲ KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol, 2020, 38(35): 4138-4148.
|
18. |
Wu D, Huang H, Zhang M, et al. The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials. J Hematol Oncol, 2022, 15(1): 16.
|
19. |
Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med, 2021, 384(13): 1191-1203.
|
20. |
Wu H, Minamide T, Yano T. Role of photodynamic therapy in the treatment of esophageal cancer. Dig Endosc, 2019, 31(5): 508-516.
|
21. |
Wu DW, Huang HY, Tang Y, et al. Clinical development of immuno-oncology in China. Lancet Oncol, 2020, 21(8): 1013-1016.
|
22. |
Yamamoto S, Kato K. JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma. Cancer Cell, 2022, 40(3): 238-240.
|
23. |
余琦瑶, 李斌, 冯海明, 等. PD-1/PD-L1在食管鳞状细胞癌中的表达及其与肿瘤预后相关性的系统评价与Meta分析. 中国胸心血管外科临床杂志, 2021, 28(11): 1352-1359.
|